A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : The aim of this study was to in ves ti ga te the phe noty pe-ge noty pe cor re la tion and the re la ti ons hip bet we en cli ni cal se ve rity sco re and acu te pha se res pon se in chil dren with fa mi li al Me di ter ra ne an fe ver (FMF) in Wes tern Tur key. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : The me di cal records of 87 FMF chil dren (me an age: 11.1 ± 3.6 ye ars; ran ge: 3-20 ye ars; me an age at di ag no sis: 8.3 ± 3.5 ye ars; me an fol low up: 31.2 ± 27.7 months; fe ma le: 55.2%) mu ta ti ons on MEFV ge ne we re retros pec ti vely re vi e wed. We used Tel Has ho mer di ag nos tic cri te ri a and se ve rity sco re. Cor re la ti ons bet we en whi te blo od cell (WBC), C-re ac ti ve pro te in (CRP) and eryt hrocy te se di men ta ti on ra te (ESR) du ring at tack-pe ri od as well as cli ni cal se ve rity sco res we re in ves ti ga ted. The pa ti ents we re gro u ped ac cor ding to one or two al le led mu ta ti ons and the pre sen ce of the M694V mu ta ti on. Clini cal pa ra me ters and WBC, CRP and ESR le vels we re com pa red among the gro ups. R Re e s su ul lt ts s: : M694V ho mozy go sity was fo und in 22 pa ti ents (25.3%). Amy lo i do sis was se en in six pa ti ents (6.9%). All of them had M694V ho mozy go te mu ta ti on. The me a su red WBC (r= 0.294; p: 0.006), CRP (r= 0.720; p< 0.001) and ESR (r= 0.716; p< 0.001) va lu es we re cor re la ted with cli ni cal se ve rity sco re. The pre sen ce of two mu ta ted al le les or M694V ho mozy go sity was as so ci a ted with a hig her cli ni cal se ve rity sco re, hig her le vels of WBC, CRP and ESR as well as hig her risk of amy lo i do sis com pa red to the others (p< 0.05). C Co on nc c l lu u s si i o on n: : M694V ho mozy go te ge noty pe shows hig her acu te pha se res pon se du ring at tack-pe ri od and se ve re cli ni cal co ur se in chil dren with FMF in Wes tern re gi on of Tur key. K Ke ey y W Wo or rd ds s: : Fa mi li al Me di ter ra ne an Fe ver; acu te-pha se re ac ti on; ge noty pe; child; Tur key Ö ÖZ ZE ET T A Am ma aç ç: : Bu ça lış ma nın ama cı Tür ki ye' nin ba tı sın da ki ai le sel Ak de niz ate şi (AA A) ta nı lı ço cuklar da fe no tip-ge no tip ko re las yo nu nu ve kli nik şid det sko ru ile akut faz ya nı tı ara sın da ki iliş ki yi araş tır mak tı. G Ge e r re eç ç v ve e Y Yö ön n t te em m l le er r: : MEFV ge nin de mu tas yon sap ta nan AA A ta nı lı 87 ço cu ğun (orta la ma yaş: 11.1 ± 3.6 yıl; ara lık: 3-20 yıl; ta nı anın da ki or ta la ma yaş: 8.3 ± 3.5 yıl; or ta la ma iz lem sü re si: 31.2 ± 27.7 ay; kız: %55.2) tıb bi ka yıt la rı ge ri ye dö nük ola rak göz den ge çi ril di. Tel Has homer ta nı kri ter le ri ve şid det sko ru kul la nıl dı. Atak sı ra sın da ki be yaz kü re sa yı sı (BKS), C-re ak tif pro te in (CRP) ve erit ro sit se di men tas yon hı zı (ESH) ile kli nik şid det sko ru ara sın da ki ko re las yonlar araş tı rıl dı. Has ta lar bir ve ya iki alel de mu tas yon ol ma du ru mu ve M694V mu tas yo nu nun var lı -ğı na gö re grup lan dı rıl dı lar. Grup lar ara sın da kli nik pa ra met re ler ile BKS, CRP ve ESH dü zey le ri kar şı laş tı rıl dı. B Bu ul l g gu u l la ar r: : Yir mi iki (%25.3) has ta da M694V ho mo zi got lu ğu bu lun du. Al tı has ta da (%6.9) ami lo i doz ge liş ti. Bun la rın ta ma mın da M694V ho mo zi got mu tas yo nu var dı. Öl çü len BKS (r= 0.294; p: 0.006), CRP (r= 0.720; p<0.001) ve ESH (r= 0.716; p< 0.001) de ğer le ri kli nik şid det sko ru ile ba ğın tı lıy dı. İki alel de mu tas yon var lı ğı ve ya M694V ho mo zi got lu ğu da ha yük sek kli nik şid det sko ru , da ha yük sek se vi ye de BKS, CRP ve ESH dü zey le ri ile da ha faz la ami lo i doz ris kiy le iliş ki liydi (p< 0.05). S So o n nu uç ç: : Tür ki ye' nin ba tı sın da M694V ho mo zi got ge no ti pi ne sa hip AA A' li ço cuk lar atak dö ne min de da ha yük sek akut faz ya nı tı ve ağır kli nik gi diş gös ter mek te dir ler.
T Tu ur rk ki iy ye e K Kl li in ni ik kl le er ri i J J M Me ed d S Sc ci i 2 20 01 11 1; ;3 31 1( (6 6) ): :1 14 41 10 0-- 7 7 Murat ANIL, MD, a mi li al Me di ter ra ne an fe ver (FMF) is an auto so mal re ces si ve di sor der cha rac te ri zed by re cur rent self-li mi ted epi so des of fe ver and se ro sal inf lam ma ti on ac com pa ni ed by a mar ked acu te-pha se res pon se. It af fects pri ma rily pe op le of Je wish, Tur kish, Arab, and Ar me ni an an ces tri es. The most de vas ta ting comp li ca ti on of FMF is amylo i do sis, le a ding to chro nic re nal fa i lu re. The frequ ency is hig her in non-Ash ke na zi Jews and Ana to li an Turks. The FMF ge ne cal led MEFV was map ped to the short arm of chro mo so me 16 . The fi ve most com mon mu ta ti ons are M694V, M680I, M694I, E148Q, and V726A. Alt ho ugh phe noty pege noty pe re la ti ons hip is not well es tab lis hed, se veral re se arc hers ha ve ob ser ved mo re se ve re di se a se ex pres si on and in cre a sed sus cep ti bi lity to amy lo ido sis in pa ti ents with M694V mu ta ti on. Ho we ver, stu di es imp li ca ted that en vi ron men tal fac tors affect the risk of de ve lo ping amy lo i do sis. [1] [2] [3] The pur po se of this study was to in ves ti ga te the phe noty pe-ge noty pe cor re la ti on and the pre dic tors of prog no sis in chil dren with FMF in the Wes tern re gi on of Tur key as ses sed by acu te pha se res pon se du ring at tack-pe ri od and cli ni cal se ve rity sco re.
MATERIAL AND METHODS
We ret ros pec ti vely re vi e wed the me di cal re cords of 87 chil dren with FMF who we re di ag no sed betwe en Ja nu ary 1996 and Ju ne 2006 and fol lo wed up for at le ast one ye ar in the Pe di at ric Nep hro logy Unit of Te pe cik Tra i ning and Re se arch Hos pi tal, Iz mir, Tur key. The ori gin of all pa ti ents was Tur kish and they we re li ving in Wes tern re gi on of Turkey. The di ag no sis of FMF was ma de ba sed on Tel Has ho mer di ag nos tic cri te ri a. 4 The me a su red whi te blo od cell co unt (WBC) (/mm 3 ), le vels of C-re ac ti ve pro te in (CRP) (by nep he lo met ric me tod; mg/dl) and eryt hrocy te se di men tati on ra te (ESR) (by Wes ter gre en met hod; mm/h) du ring at tack-pe ri od we re re cor ded. Ge no mic DNA was ex trac ted from pa ti ents by ob ta i ning 5 ml of who le blo od using the con ven ti o nal phe nol-chlo roform ex trac ti on met hod. A re ver se hybri di za ti on assay (FMF Stri pAs say, Vi en na Lab La bor di ag nos ti ka, Vi en na, Aus tri a) was used for the de tec ti on of the 12 most fre qu ent MEFV mu ta ti ons lo ca ted in exon 2, p.E148Q (c.442G>C); exon 3, p.P369S (c.1105C>T); exon 5, p.F479L (c.1437C>G); and exon 10, p.M680I (c.2040G>C), p.M680I (c.2040G>A), I692del (c.2076>2078del), p.M694V (c.2080A>G), pM694I (c.2082G>A), p.K695R (c.2084A>G), p.V726A (c.2177T>C), p.A744S (c.2230G>T), and p.R761H (c.2282G>A). Da ta were col lec ted from the me di cal charts and, if ne ces sary by in ter vi ew. Res pon se to colc hi ci ne tre at ment was eva lu a ted as comp le te (attack fre e), in comp le te (dec li ne >50% in the fre qu ency of at tacks) and un res pon si ve, ac cor ding to cli ni cal con di ti on. The se ve rity sco re of the di se a se was calcu la ted ba sed on the Tel Has ho mer Se ve rity Sco re, 5 inc lu ding the pa ra me ters of age of on set (<5 ye ars: 3, 5-10 ye ars: 2, 10-20 ye ars: 1, >20 ye ars: 0), fre qu ency of at tacks (>2 per month: 3, 1-2 per month: 2, <1 per month: 1), colc hi ci ne do sa ge to con trol at tacks (nonres pon der: 4, 2 mg/day: 3, 1.5 mg/day: 2, 1 mg/day: 1), art hri tis (prot rac ted art hri tis: 3, pre sen ce of acu te jo ints: 2), ery si pe las-li ke ery the ma (2 po ints), amy loi do sis (3 po ints) and phe noty pe II (4 po ints). Pa ti ents pre sen ting with amy lo i do sis be fo re the on set of cli ni cal symptoms of FMF we re de sig na ted as ha ving phe noty pe II. In pa ti ents with per sis tent pro te i nu ri a or nep hro tic syndro me, a kid ney bi opsy was do ne. The his to lo gi cal di ag no sis of amy lo i do sis was con firmed by the pre sen ce of amy lo id de po sits on Con go red sta i ning un der po la ri zed light mic ros copy.
Da ta we re analy zed using SPSS 13.0 (Chi ca go, IL, USA) sta tis ti cal prog ram. Con ti no us va ri ab les me a su red as ratios were as su med to be nor mally dis tri bu ted and ex pres sed as me an±SD (stan dart devi a ti on). Me di an and in ter qu ar ti le ran ge (IQR) were used for the ot her va ri ab les which were ex pres sed as co unt da ta and were not nor mally dis tri bu ted. For the va ri ab les which were nor mally dis tri bu ted, Student t-test (bet we en two in de pen dent gro ups), and one-way ANO VA (among mo re than two gro ups) were used to test equality of the me ans of the dif ferent gro ups. Mann-Whit ney U test and Krus ka lWal lis test are non pa ra met ric al ter na ti ves of Stu dent t-test and ANO VA, res pec ti vely. They do not rely on an as sump ti on of nor ma lity. For ot her va ri ab les, Mann-Whit ney U and Krus kal-Wal lis tests we re used to eva lu a te the dif fe ren ces bet ween gro ups. We com pa red ca te go ri cal da ta with Chi-Anıl ve ark.
Çocuk Romatoloji squ a re test. The cor re la ti ons bet we en WBC, CRP, ESR and se ve rity sco re we re analy zed by Spe arman's cor re la ti on met hod. A p-va lu e less than 0.05 was con si de red as sig ni fi cant.
This study was ap pro ved by the hos pi tal et hics com mit te e.
RESULTS
The di ag no sis of 87 pa ti ents (48 girls, 39 boys) with cli ni cally de fi ned FMF was con fir med by mu ta ti on analy sis. The me an age of pa ti ents was 11.1±3.6 years (ran ge: 3-20; me di an age: 11 ye ars). Me an fol low up duration was 31.2±27.7 months (ran ge: 12-128; me di an fol low up: 24). All sub jects we re phe noty pe I pa ti ents. Ni ne pa ti ents (10.3%) had pro te i nu ri a. Re nal bi opsy re ve a led amy lo i do sis in six pa ti ents (6.9%). Remaining three pa ti ents we re di ag no sed with IgA nep hro pathy. Tab le 1 sum ma ri zes de mograp hic and phe noty pic fe a tu res of the study gro up.
In the ge ne tic analy ses, the num ber of homozy go tes, he terozy go tes and com po und he terozy go tes we re 22 (25.3%), 18 (20.7%) and 13 (14.3%), res pec ti vely. Ho mozy go sity for M694V was the most fre qu ent mu ta ti on (22 pa ti ents, 25.3%). The me an se ve rity sco re of ho mozy go tes for M694V mu ta ti on was 10.5±2.6. Hig her WBC, CRP and ESR le vels we re fo und du ring at tack-pe ri od in M694V ho mozy go te or com po und he te rozy go te ge noty pes compared to the ot hers (Tab le 2).
WBC (r= 0.294; P= 0.006), CRP (r= 0.720; P<0.001) and ESR (r= 0.716; P<0.001) le vels we re sig ni fi cantly cor re la ted with se ve rity sco re in FMF pa ti ents (Fi gu res 1-3).
Pa ti ents we re di vi ded in to two gro ups ac cording to the num ber of mu ta ted al le les (Tab le 3).
Pre sen ce of two mu ta ted al le les was as so ci a ted with a yo un ger age at on set (P=0.005), mo re fre quent art hri tis (P=0.007), hig her num ber of at tacks Anıl ve ark. Çocuk Romatoloji
Our pa ti ents we re al so clas si fi ed in to thre e gro ups ac cor ding to mu ta ti ons: Met694Val-Met694Val (gro up 1), Met694Val-ot her (gro up 2, inc lu ding Met694Val he te rozy go te or com po und he te rozy go te) and ot her-ot her (gro up 3) (Tab le 4).
Gro ups 1 and 2 we re as so ci a ted with yo un ger age at on set (P<0.001) and hig her WBC (P=0.012), ESR (P<0.001) and CRP (P<0.001) le vels. The shortest in ter val bet we en di se a se on set and di ag no sis was fo und in Gro up 2 (P<0.001). Art hri tis (P<0.001), ery si pe las-li ke ery the ma (P=0.003), prote i nu ri a (P=0.001) and amy lo i do sis (P<0.001) we re mo re fre qu ent in Gro up 1. Sig ni fi cant dif fe ren ces we re de tec ted bet we en the gro ups with re gard to the ra te of res pon se to colc hi ci ne tre at ment, number of at tacks per ye ar be fo re and af ter tre at ment 
One mutated allele
Two mutated alleles and se ve rity sco re. The greatest num ber of at tacks per ye ar be fo re and af ter tre at ment we re fo und in Gro up 1 whe re as the smallest num ber of at tacks be fo re and af ter tre at ment we re fo und in Gro up 3 (P<0.001). Gro up 1 sho wed the hig hest se ve rity sco re and the lo west ra te of res pon se to colc hi ci ne tre at ment whe re as Gro up 3 ex pe ri en ced the lo west se ve rity sco re and the hig hest ra te of res pon se to colc hi ci ne tre at ment (P<0.001).
DISCUSSION
This sing le-cen ter study from Wes tern re gi on of Tur key in ves ti ga ted 87 chil dren with FMF in whom the MEFV al le les had be en iden ti fi ed to de ter mi ne the phe noty pe-ge noty pe as so ci a ti on and risk fac tors for amy lo i do sis. Alt ho ugh a ma le pre do mi nan ce has be en re por ted in Arab, Ar me ni an, and Je wish and Tur kish pa ti ents, we ob ser ved a slight fe ma le su peri o rity (ma le:fe ma le ra ti o of 1:1.2). 2, [6] [7] [8] [9] [10] In addition, the age of the di se a se on set and the di ag no sis we re fo und to be smaller compared to lar ge stu di es and si mi lar to a study from Tur key. 2, 9, 11 In our se ri es, abdo mi nal pa in was the most com mon fe a tu re (97.7%), fol lo wed by fe ver (72.4%) and jo int in volve ment (58.6%). The se fin dings we re si mi lar to the re sults of ot her stu di es on Turkish and Jewish so cie ti es. 2, 8, 9, 11, 12 The ra tes of ery si pe las-li ke ery the ma (17.2%), myal gi a (8%) and ple u ri tis (5.7%) we re lo - wer than Tur kish FMF Study Gro up re cords but simi lar to the re port from Cen tral Ana to li a. 2, 11 The ra te of ery si pe las-li ke ery the ma in our study was hig her than Arabs and Ar me ni ans. 13, 14 The fi ve most com mon mu ta ti ons are M694V, M680I, M694I, E148Q, and V726A. 1, 3 The Met694Val mu ta ti on was the most com mon one (60.9%) of the tes ted al le les in our study gro up, as re por ted in ot her stu di es from Tur key. 1, 2, 9, 11, 12 In teres tingly, the se cond most fre qu ent mu ta ti on was E148Q (18.4%) in the pre sent study.
It is well known that in cre a sed acu te pha se res pon se du ring at tacks is a cha rac te ris tic fin ding of FMF. Mo re o ver, FMF pa ti ents may al so show higher acu te pha se res pon se in the ir at tack-fre e pe riods du e to on go ing subc li ni cal inf lam ma ti on. 1, 3 Tun ca et al. re por ted hig her CRP and se rum amylo id A pro te in (SA A) le vels in pa ti ents with FMF and the ir he althy first-deg re e re la ti ves. 15 Du zo va et al. fo und that SA A (not CRP, ESR, fib ri no gen or fer ri tin) was the best mar ker of on go ing subc li nical inf lam ma ti on in FMF pa ti ents. 16 Kork maz et al. sho wed a mar ked acu te pha se res pon se du ring FMF at tacks and high CRP le vels in all at tacks. 17 On the other hand, a study on li mi ted num ber of pa ti ents from the Ae ge an re gi on by Türk men et al., re por ted that ho mozy go sity for M694V did not af fect acu te pha se mar kers. 18 In the pre sent study, we ob ser ved that high le vels of WBC, CRP and ESR du ring the at tack-pe ri od we re as so ci a ted with high se ve rity sco res. In the pre sen ce of M694V ge noty pe, high WBC, CRP and ESR le vels we re me a su red du ring the at tack-pe ri od. The se results may sup port the se ve rity of M694V mu ta ti on on la bo ra tory ba sis. Un for tu na tely, we co uld not me a su re SA A le vel of the pa ti ents du e to no na vai la bi lity. To our know led ge, this is the first study that investigates the re la ti ons hip bet we en acu te pha se pro te ins du ring at tack-pe ri od and cli ni cal se ve rity sco re in pa ti ents with FMF.
In our se ri es, two mu ta ted al le les we re M694V ho mozy go tes (25.3%), M694V com po und he terozy go tes (14.9%), and ho mozy go tes for other alleles and ot her com po und he te rozy go te ge noty pes (10.3%). The fin dings of the pre sent study con firmed that any two mu ta ti ons, as com pa red with one mutation, cor re la ted with more severe di se a se. 19 We fo und that ear li er age, hig her at tack ra te be fore and af ter tre at ment, hig her se ve rity sco re, low res pon se ra te to colc hi ci ne tre at ment, hig her ra te of pro te i nu ri a and amy lo i do sis as well as hig her WBC, CRP and ESR le vels we re as so ci a ted with the pre sen ce of two mu ta ted al le les. The sig ni fi cantly hig her acu te-pha se res pon se in at tack pe ri od we re de tec ted in patients with two mu ta ted al le les compared to tho se with one mu ta ted al le le. It is cle arly se en that increased cli ni cal and la bo ra tory se ve rity of the two mu ta ted al le les which inc lu ded M694V mu ta ti on most of the time, was re la ted to the pre sen ce of M694V ge noty pe in the pre sent study.
The most de vas ta ting comp li ca ti on of FMF is amy lo i do sis, which af fec ts the kid neys le a ding to chro nic re nal fa i lu re. The pre va len ce of amy lo i dosis dif fers among va ri o us eth nic gro ups. 1, 3 Amy lo ido sis was re por ted as 2% in Arabs, 27.6% in Sep har dic Jews, 24% in Ar me ni ans and 12.9% in Turks. 1, 2, 8, 13 In the pre sent study, amy lo i do sis was fo und in 6.9% of the pa ti ents.
The ge noty pe-phe noty pe cor re la ti on is not well es tab lis hed. 1 Se ve ral stu di es from dif fe rent coun tri es as well as dif fe rent re gi ons of Tur key ha ve emp ha si zed that M694V ho mozy go us ge noty pe have a mo re se ve re form of di se a se ma ni fes ted by an ear li er age of on set, hig her fre qu ency of at tacks, hig her pre va len ce of art hri tis and ple u risy, hig her fre qu ency of amy lo i do sis and hig her se ve rity scores compared to the ot her ge noty pes. 2, 11, [20] [21] [22] [23] [24] [25] On the con trary, so me stu di es sho wed that the pre sen ce of M694V mu ta ti on was not fo und to be as so ci a ted with a se ve re form of the di se a se or the de ve lopment of amy lo i do sis. 2, 9, 11 Re cently, in a lar ge co hort study from the Ae ge an re gi on of Tur key, the M694V ho mozy go us mu ta ti on was fo und most frequ ently in a de fi ni ti ve FMF gro up, ba sed on TelHas ho mer cri te ri a. 26 In Wes tern re gi on of Tur key, we fo und that M694V ho mozy go te mu ta ti on was as so ci a ted with a se ve re cli ni cal co ur se whe re as E148Q mu ta ti on was as so ci a ted with a pre fe rab le cli ni cal co ur se. Ear li er age at onset of di se a se, higher fre qu en ci es of art hri tis, ery si pe las-li ke ery thema and myal gi a, hig her at tack ra te and se ve rity sco re, low res pon se ra te to colc hi ci ne tre at ment, and hig her le vels of WBC, CRP and ESR du ring attack-pe ri od we re as so ci a ted with the pre sen ce of M694V mu ta ti on in our study. The ge noty pes of all pa ti ents with pro te i nu ri a and amy lo i do sis inc lu ded M694V mu ta ti on at le ast in one al le le, and all of the pa ti ents with amy lo i do sis had M694V ho mozygo te ge noty pe. In te res tingly, the ti me in ter val bet we en di se a se on set and di ag no sis in chil dren with Met694Val-ot her mu ta ti on (Gro up 2) was sig ni ficantly lon ger than the ot hers. Furt her mo re, alt hough in sig ni fi cant, the shor test in ter val was fo und in non-Met694Val ge noty pes. It is li kely that the la ter on set of the di se a se in the se chil dren co uld be as so ci a ted with the ear li er di ag no sis du e to ea si er ex pres si on of the comp la ints in the ol der age.
To our know led ge, this study high lights so me im por tant fe a tu res. Firstly, this is the first study which as ses sed the chil dren with FMF li ving in Wes tern re gi on of Tur key. Se condly, this re port is the first that sho wed a po si ti ve cor re la ti on bet ween the le vel of acu te pha se res pon se in at tack-pe riod and the se ve rity of cli ni cal sco re.
CONCLUSION
This study sho wed a phe noty pe-ge noty pe cor re la tion in FMF pa ti ents li ving in Wes tern re gi on of Turkey. In conc lu si on, we have re ve a led that M694V ho mozy go sity is as so ci a ted with a mo re se ve re cour se and de ve lop ment of amy lo i do sis when com pared to ot her com mon ge noty pes in our re gi on.
